Yaya Capital

ISA lab is to deliver the best solution for health and offers a humanized service. ISA is an online platform where one can select the process like examination, test, or vaccine. Then schedule and make payment online, receive ISA wherever one wants. Finally, they offer a facility to check the result online and rate their service.

Endpoint Health, Inc. researches and develops therapies by combining therapeutics, companion diagnostics, and artificial intelligence into an integrated platform. It develops therapies to improve the outcomes of patients with critical illnesses, such as sepsis, acute respiratory distress syndrome, and COVID-19. Endpoint Health, Inc. was founded in 2018 and is headquartered in Palo Alto, California. It has additional offices in Detroit and Livonia, Michigan; and Chicago, Illinois.

Klivo is a health technology company that operates a patient management platform designed to support individuals with chronic conditions in leading healthier lives. The platform enables real-time monitoring of health conditions and facilitates the transmission of blood glucose data. Additionally, it provides users with answers to questions related to clinical conditions, nutrition, and other relevant topics. By equipping healthcare professionals with essential data and insights, Klivo aims to enhance clinical outcomes for patients managing chronic illnesses.

Endpoint Health, Inc. researches and develops therapies by combining therapeutics, companion diagnostics, and artificial intelligence into an integrated platform. It develops therapies to improve the outcomes of patients with critical illnesses, such as sepsis, acute respiratory distress syndrome, and COVID-19. Endpoint Health, Inc. was founded in 2018 and is headquartered in Palo Alto, California. It has additional offices in Detroit and Livonia, Michigan; and Chicago, Illinois.

Metagenomi, Inc. is a genetic medicines company based in Emeryville, California, focused on developing innovative gene editing systems for the treatment of genetic diseases. Since its incorporation in 2016, the company has utilized a proprietary metagenomics-derived genome editing toolbox that enables the creation of curative therapeutics. This toolbox encompasses a range of advanced technologies, including programmable nucleases, base editors, and various RNA and DNA-mediated integration systems, such as prime editing systems and CRISPR-associated transposases (CASTs). Metagenomi aims to address the challenges posed by diverse mutations that have traditionally been difficult to target with existing genome engineering approaches.